You are here » Home » Companies » Company Overview » Syncom Formulations (India) Ltd

Syncom Formulations (India) Ltd.

BSE: 524470 Sector: Health care
NSE: N.A. ISIN Code: INE312C01025
BSE LIVE 15:40 | 23 Aug 1.42 0.01
(0.71%)
OPEN

1.44

HIGH

1.47

LOW

1.40

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 1.44
PREVIOUS CLOSE 1.41
VOLUME 667993
52-Week high 2.95
52-Week low 1.40
P/E 10.92
Mkt Cap.(Rs cr) 111
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 1.44
CLOSE 1.41
VOLUME 667993
52-Week high 2.95
52-Week low 1.40
P/E 10.92
Mkt Cap.(Rs cr) 111
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Syncom Formulations (India) Ltd. (SYNCOMFORMUL) - Company History

Incorporated as a private limited company in 1988, Syncom Formulations (India) was converted into a public limited company in Jun.'92. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda. In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis. In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995. During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations. During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%. During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.